Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection

Journal of Infectious Diseases

Volumn 183, Issue 6, 2001, Pages 943-952

  Linke, Michael J ^a   Harris, Christopher E ^b,c   Korfhagen, Thomas R ^b   McCormack, Francis X ^a   Ashbaugh, Alan D ^a   Steele, Paul ^b   Whitsett, Jeffrey A ^b   Walzer, Peter D ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPSONIN; SURFACTANT PROTEIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; HOST RESISTANCE; IMMUNE DEFICIENCY; INFECTION; LUNG ALVEOLUS MACROPHAGE; MOUSE; NONHUMAN; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PRIORITY JOURNAL;

ANIMALS; BACTERIAL ADHESION; CELLS, CULTURED; DISEASE SUSCEPTIBILITY; ENVIRONMENTAL EXPOSURE; IMMUNOCOMPROMISED HOST; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; PROTEOLIPIDS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; PULMONARY SURFACTANTS; TRACHEA;

EID: 0035869184     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/319252     Document Type: Article

References (61)

1. Pneumocystis carinii pneumonia ill patients without acquired immunodeficiency syndrome: Associated illness and prior corticosteroid therapy
2. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group
3. Alveolar macrophage interaction with Pneumocystis carinii
4. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung
5. Steady-state effects of vitronectin and fibronectin on the binding, uptake, and degradation of Pneumocystis carinii in rat alveolar macrophages
6. Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages
7. Vitronectin, fibronectin, and gp120 antibody enhance macrophage release of TNF-α in response to Pneumocystis carinii
8. Pneumocystis carinii induces the release of arachidonic acid and its metabolites from alveolar macrophages
9. Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms
10. Pneumocystis carinii stimulates tumor necrosis factor-α release from alveolar macrophages through a β-glucan-mediated mechanism
11. Alveolar macrophage release of tumor necrosis factor during murine Pneumocystis carinii pneumonia
12. Human immunodeficiency virus type I infection of human macrophages modulates the cytokine response to Pneumocystis carinii
13. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation
14. Collectins: Pattern recognition molecules involved in first line host defense
15. Structures and functions associated with the group of mammalian lectins containing collagen-like sequences
16. Purification of a cell-surface receptor for surfactant protein A
17. Specific binding of surfactant apoprotein SP-A to rat alveolar macrophages
18. Immunomodulatory functions of surfactant
19. Surfactant protein A and surfactant protein D in health and disease
20. Interactions of surfactant protein A with influenza A viruses: Binding and neutralization
21. Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides
22. Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages
23. Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages
24. Binding of surfactant protein A (SP-A) to herpes simplex virus type 1-infected cells in mediated by the carbohydrate moiety of SP-A
25. Exposure of surfactant protein A to ozone in vitro and in vivo impairs its interactions with alveolar cells
26. Nitrated SP-A does not enhance adherence of Pneumocystis carinii to alveolar macrophages
27. The carbohydrate recognition domain of surfactant protein A mediates binding to the major surface glycoprotein of Pnemocystis carinii
28. Pneumocystis carinii alters surfactant protein A concentrations in bronchoalveolar lavage fluid
29. Phospholipid composition of Pneumocystis carinii carinii and effects of methylprednisolone immunosuppresseion on rat lung lipids
30. Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat
31. Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages
32. Surfactant protein-A reduces binding and phagocytosis of Pneumocystis carinii by human alveolar macrophages in vitro
33. Surfactant protein A (SP-A) gene targeted mice
34. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection
35. Surfactant protein-A-deficient nice are susceptible to Pseudomonas aeruginosa infection
36. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo
37. Experimental Pneumocystis carinii pneumonia in different strains of cortisonized mice
38. Pneumocystis carinii pneumonia in scid/scid mice
39. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs
40. Inoculated mouse model of Pneumocystis carinii infection
41. Mouse model for Pnemocystis carinii pneumonia that uses natural transmission to initiate infection
42. Pneumocystis carinii pneumonia in thoroughbred foals: Identification of a genetically distinct organism by DNA amplification
43. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon
44. New rapid method for the study of Pneumocystis carinii interaction with alveolar macrophages
45. Normal surfactant pool sizes and inhibition-resistant surfactant from mice that overexpress surfactant protein A
46. Properties of the major antigens of rat and human Pneumocystis carinii
47. Decreased surfactant protein A in patients with bacterial pneumonia
48. Alveolar macrophage and glycoprotein responses to Pneumocystis carinii
49. 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A
50. Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice
51. Surfactant protein-A binds group B streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-A-deficient mice
52. Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages
53. SP-A enhances phagocytosis of Klebsiella by interaction with capsular polysaccharides and alveolar macrophages
54. Opsonophagocytosis of Pneumocystis carinii
55. The interaction in vitro of Pneumocystis carinii with macrophages and L-cells
56. Neutrophil cheriotactic activity in bronchoalveolar lavage fluid of patients with AIDS-associated Pneumocystis carinii pneumonia
57. Interleukin-8 and eicosanoid production in the lung during moderate to severe Pneumocystis carinii pneumonia in AIDS: A role of interleukin-8 in the pathogenesis of P. carinii pneumonia
58. Pneumocystis carinii pneumonia: Differences in lung parasite number and inflammation in patients with and without AIDS
59. Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat
60. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia
61. Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo